ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

CNTG Centogene NV

0,4406
0,0066 (1,52%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Centogene NV CNTG NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,0066 1,52% 0,4406 06:00:02
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,438 0,43 0,4557 0,442851 0,434
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
02.4.202422:30GLOBECENTOGENE Receives Nasdaq Non-Compliance Notice
19.3.202411:30GLOBECENTOGENE Extends Strategic Partnership With Takeda to..
29.2.202423:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.2.202423:00GLOBECENTOGENE Collaborates on Research Published in Science..
28.2.202412:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.2.202412:30GLOBECENTOGENE Announces Receipt of Nasdaq Notice of Delisting..
28.2.202412:30GLOBECENTOGENE Explores Strategic Alternatives
28.2.202412:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25.1.202412:30GLOBECENTOGENE and the Laboratory of Human Genetics of Infectious..
25.1.202412:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24.1.202412:30GLOBECENTOGENE Receives French Research Tax Credit Accreditation
24.1.202412:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23.1.202412:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23.1.202412:30GLOBECENTOGENE and The Michael J. Fox Foundation Announce..
18.1.202413:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.1.202412:30GLOBECENTOGENE Announces Preliminary Full Year 2023 Revenue
19.12.202313:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19.12.202312:30GLOBECENTOGENE Announces Voting Results of Extraordinary General..
18.12.202312:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13.12.202312:33EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13.12.202312:30GLOBECENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study,..
01.12.202312:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.11.202312:30GLOBECENTOGENE and Lifera, a Public Investment Fund (PIF)..
28.11.202312:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.11.202314:30GLOBECENTOGENE, University College London, and Global Team of..
03.11.202321:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27.10.202313:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10.10.202312:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10.10.202312:30GLOBECENTOGENE Expands Multiomic Diagnostic Portfolio With..
06.10.202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.9.202314:30GLOBECENTOGENE to Present at H.C. Wainwright 25th Annual Global..
07.9.202323:00GLOBECENTOGENE Reports First Half 2023 Financial Results
07.9.202323:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.9.202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.9.202314:00GLOBECENTOGENE Announces Publication Establishing Lyso-Gb1 as a..
31.8.202322:30GLOBECENTOGENE Receives Nasdaq Non-Compliance Notification..
31.8.202322:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.8.202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.8.202312:30GLOBECENTOGENE to Participate in Upcoming Conferences in August
14.7.202312:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.7.202312:30GLOBECENTOGENE Regains Compliance With Nasdaq Listing..
12.7.202313:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12.7.202313:30GLOBECENTOGENE Biodatabank Reveals Unique Genetic Variants in..
02.7.202311:00PRNUSLifera and CENTOGENE, Enter Strategic Collaboration -..
30.6.202322:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30.6.202322:30GLOBECENTOGENE Announces Approval of All Resolutions Tabled at..
27.6.202313:30GLOBECENTOGENE and Lifera, a Biopharma Company Owned by the PIF,..
14.6.202322:30GLOBECENTOGENE Receives Nasdaq Notification Regarding Minimum..
17.5.202300:25GLOBECENTOGENE Reports Full Year 2022 Financial Results

Kürzlich von Ihnen besucht

Delayed Upgrade Clock